HARMONY BIOSCIENCES HOLDINGS, INC. Income Tax Expense
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Income Tax Expense of $17.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $17.83M, a 80.85% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $7.20M, a 38.03% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $18.27M, a 173.56% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was $16.63M, a 3.41% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for fiscal 2025 was $56.38M, a 21.74% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for fiscal 2024 was $46.31M, a 3.97% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for fiscal 2023 was $44.54M.
- HARMONY BIOSCIENCES HOLDINGS, INC. income tax expense (benefit) for fiscal 2022 was -$76.78M, a 2812.19% decline from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.83M 10-Q · filed 2026-08-04 | $25.03M 10-Q · filed 2026-08-04 | $43.31M derived: sum of 3 quarters · filed 2026-08-04 | $59.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.20M 10-Q · filed 2026-05-07 | $25.47M derived: sum of 2 quarters · filed 2026-05-07 | $42.10M derived: sum of 3 quarters · filed 2026-05-07 | $51.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $34.90M derived: sum of 2 quarters · filed 2026-02-24 | $44.76M derived: sum of 3 quarters · filed 2026-08-04 | $56.38M 10-K · filed 2026-02-24 |
| 2025-09-30 | $16.63M 10-Q · filed 2025-11-04 | $26.49M derived: sum of 2 quarters · filed 2026-08-04 | $38.10M 10-Q · filed 2025-11-04 | $44.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $9.86M 10-Q · filed 2026-08-04 | $21.48M 10-Q · filed 2026-08-04 | $28.16M derived: sum of 3 quarters · filed 2026-08-04 | $44.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $11.62M 10-Q · filed 2026-05-07 | $18.30M derived: sum of 2 quarters · filed 2026-05-07 | $34.37M derived: sum of 3 quarters · filed 2026-05-07 | $44.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $22.76M derived: sum of 2 quarters · filed 2026-02-24 | $32.86M derived: sum of 3 quarters · filed 2026-02-24 | $46.31M 10-K · filed 2026-02-24 |
| 2024-09-30 | $16.08M 10-Q · filed 2025-11-04 | $26.18M derived: sum of 2 quarters · filed 2025-11-04 | $39.63M 10-Q · filed 2025-11-04 | $52.71M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $10.10M 10-Q · filed 2025-08-05 | $23.55M 10-Q · filed 2025-08-05 | $36.64M derived: sum of 3 quarters · filed 2026-02-24 | $50.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $13.45M 10-Q · filed 2025-05-06 | $26.53M derived: sum of 2 quarters · filed 2026-02-24 | $39.90M derived: sum of 3 quarters · filed 2026-02-24 | $49.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $13.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $26.45M derived: sum of 2 quarters · filed 2026-02-24 | $36.25M derived: sum of 3 quarters · filed 2026-02-24 | $44.54M 10-K · filed 2026-02-24 |
| 2023-09-30 | $13.37M 10-Q · filed 2024-10-29 | $23.17M derived: sum of 2 quarters · filed 2024-10-29 | $31.46M 10-Q · filed 2024-10-29 | $27.05M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $9.79M 10-Q · filed 2024-08-06 | $18.09M 10-Q · filed 2024-08-06 | $13.68M derived: sum of 3 quarters · filed 2025-02-25 | -$66.29M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $8.29M 10-Q · filed 2024-04-30 | $3.89M derived: sum of 2 quarters · filed 2025-02-25 | -$76.09M derived: sum of 3 quarters · filed 2025-02-25 | -$70.39M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$84.38M derived: sum of 2 quarters · filed 2025-02-25 | -$78.68M derived: sum of 3 quarters · filed 2025-02-25 | -$76.78M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$79.98M 10-Q · filed 2023-10-31 | -$74.28M derived: sum of 2 quarters · filed 2023-10-31 | -$72.38M 10-Q · filed 2023-10-31 | -$70.61M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $5.70M 10-Q · filed 2023-08-01 | $7.60M 10-Q · filed 2023-08-01 | $9.36M derived: sum of 3 quarters · filed 2024-02-22 | $8.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-02 | $3.66M derived: sum of 2 quarters · filed 2024-02-22 | $2.76M derived: sum of 3 quarters · filed 2024-02-22 | $4.73M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $859.00K derived: sum of 2 quarters · filed 2024-02-22 | $2.83M derived: sum of 3 quarters · filed 2024-02-22 | $2.83M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$902.00K 10-Q · filed 2022-11-01 | $1.07M derived: sum of 2 quarters · filed 2022-11-01 | $1.07M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $1.97M 10-Q · filed 2022-08-02 | $1.97M 10-Q · filed 2022-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |